1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6FDE6872E3EB303656525850C003820EE
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-resourcing-successful-product-launch-investment-benchmarks?opendocument
18
19opendocument
2018.206.194.134
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




» Products & Services » » Product Launch » Resource Allocation

Resourcing a Successful Product Launch: Investment Benchmarks

ID: 5597


Features:

5 Info Graphics

37 Data Graphics

520+ Metrics


Pages/Slides: 56


Published: 2020


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from “Resourcing a Successful Product Launch: Investment Benchmarks”

STUDY OVERVIEW

As indications become more crowded, and the needs and influence of external stakeholders continue to evolve, pharma companies must make optimal product launch investment decisions that reflect both the opportunity at hand and the competitive environment.

To support new product launch investment decisions at pharmaceutical and biotechnology companies, Best Practices, LLC conducted a research study that benchmarks the investment required for a successful new product launch in the U.S. market. This study includes cost benchmarks for each of the three years prior to launch as well as the launch year.

This research will support brand and marketing leaders in developing optimal resourcing plans and allocations for new brands based on peak-year sales forecast, product type, and physician type.

KEY TOPICS

  • Industry investments for new pharmaceutical product launch from 3 years prior to launch, through launch year
  • Setting investment plans by year across peak year sales forecasts (PYSF)
  • PYSF investment distribution
  • Launch investment benchmarks by therapeutic area
  • Launch investment benchmarks by physician type
  • Launch investment benchmarks by drug type

KEY METRICS
  • Indicate total U.S. investment for pre-launch activities for your product in the three years prior to the U.S. product launch
  • Total year – 3 investment distribution by PYSF
  • Total year – 2 investment distribution by PYSF
  • Total year – 1 investment distribution by PYSF
  • Total launch year investment distribution by PYSF

SAMPLE KEY FINDINGS
  • Early investment (Year – 3 & Year – 2) is less than 1/4th of total spend for all 4 years. Resource needs make their largest leap going into Year – 1, while Launch year investment growth is driven by new commercial demands.

METHODOLOGY

Best Practices, LLC engaged 48 marketing and commercial leaders from 38 leading pharmaceutical, biotech, and life sciences companies through a benchmarking survey instrument, capturing resourcing efforts from 51 product launches. More than 80% of the benchmark participants serve at the director level and above.


Industries Profiled:
Health Care; Pharmaceutical; Diagnostic; Biotech; Medical Device; Manufacturing; Consumer Products; Chemical; Biopharmaceutical


Companies Profiled:
Abbott; AbbVie; Agenus; Astellas; Baxter International; Bayer; Biogen; Boehringer Ingelheim; CSL Behring; Cutanea Life Sciences; Dicerna Pharmaceuticals; EMD Serono; Ferozsons Laboratories Limited; Ferring Pharmaceuticals; Genentech; GlaxoSmithKline ; Grünenthal; Inspire Pharmaceuticals; Ipsen; Lilly; Lundbeck; Lupin; Nektar Therapeutics; Novartis; Noven Pharmaceuticals; Novo Nordisk; OncoCyte; OTSUKA; Pharmacyclics; Regeneron; Roche; Santhera Pharmaceuticals; Sebela; Servier; Shire; Sunovion; Takeda Pharmaceuticals; Tesaro; Teva Pharmaceutical Industries Ltd; Zydus Cadila

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.